Ranbaxy Laboratories has received an approval from the US Food and Drug Administration (FDA) to manufacture and market Furosemide tablets USP, 20 mg, 40 mg, and 80 mg.According to a release issued by Ranbaxy to the BSE, the USFDA has determined the company's formulations to be the bio-equivalent of the reference listed drug Lasix tablets, 20 mg, 40 mg, and 80 mg, respectively, of Aventis Pharmaceuticals."The approval is the result of a strategic alliance with Ipca Laboratories, which will develop a number of generic prescription pharmaceutical products to be marketed by Ranbaxy in the US in the future," Jim Meehan, vice president, US sales and marketing of Ranbaxy, said.
